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Abstract
Interferons (IFNs) have been shown to negatively regulate osteoclastogenesis.
In a proteomic study to assess protein expression during osteoclastogenesis,
we discovered that the expression level of Jak1 was significantly decreased
during the early stage of osteoclast differentiation from mouse bone marrow
macrophages (BMMs) upon stimulation with receptor activator of nuclear factor
kappaB ligand (RANKL). RANKL induced Jak1 ubiquitination, and a proteasome
inhibitor MG132 efficiently blocked the RANKL-induced degradation of Jak1.
The expression level of Jak1 correlated with the susceptibility of osteoclast
precursors to the negative regulatory effects of IFN-beta on osteoclastogenesis,
since preosteoclasts (pOCs) in which Jak1 expression is significantly reduced
could proceed with osteoclastogenesis in the presence of IFN-beta. Forced down-
regulation of Jak1 by small interfering RNA (siRNA) resulted in the efficient
osteoclast differentiation of BMMs in the presence of inhibitory IFN-...
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Interferons (IFNs) have been shown to
negatively regulate osteoclastogenesis.
In a proteomic study to assess protein
expression during osteoclastogenesis, we
discovered that the expression level of
Jak1 was significantly decreased during
the early stage of osteoclast differentia-
tion from mouse bone marrow macro-
phages (BMMs) upon stimulation with
receptor activator of nuclear factor B
ligand (RANKL). RANKL induced Jak1
ubiquitination, and a proteasome inhibi-
tor MG132 efficiently blocked the RANKL-
induced degradation of Jak1. The expres-
sion level of Jak1 correlated with the
susceptibility of osteoclast precursors to
the negative regulatory effects of IFN-
on osteoclastogenesis, since preoste-
oclasts (pOCs) in which Jak1 expression
is significantly reduced could proceed
with osteoclastogenesis in the presence
of IFN-. Forced down-regulation of Jak1
by small interfering RNA (siRNA) resulted
in the efficient osteoclast differentiation
of BMMs in the presence of inhibitory
IFN-, while overexpression of Jak1 in
pOCs elicited IFN-–dependent inhibition
of osteoclastogenesis. Furthermore, we
found that the IFN-–induced inhibition
of osteoclastogenesis required STAT3
downstream of Jak1. These data suggest
that the regulation of Jak1 expression
during osteoclast differentiation might
serve as an intrinsic mechanism that de-
termines osteoclast lineage commitment
by modulating the negative regulation by
IFN-. (Blood. 2008;111:885-893)
© 2008 by The American Society of Hematology
Introduction
Osteoclasts (OCs) are multinucleated cells for bone resorption
originated from the monocyte/macrophage lineage of hematopoi-
etic cells.1,2 OC differentiation from its precursor is a multistep
process requiring both macrophage colony-stimulating factor (M-
CSF) and receptor activator of nuclear factor B ligand (RANKL).3
The precursor cells first differentiate into mononuclear preoste-
oclasts (pOCs) and fuse to form multinucleated OCs. M-CSF
induces expression of RANKL receptor (RANK) as well as
supports survival and proliferation of OC precursors.3 RANKL
stimulates differentiation of precursors into OCs by inducing the
expression of OC-specific genes, including tartrate-resistant acid
phosphatase (TRAP), cathepsin K, and calcitonin receptor.1,2,4
RANKL is also required for the survival and activity of mature
OCs.1,2 Although more detailed mechanism is still expected to be
unveiled, RANKL signaling includes the recruitment of TNF
receptor–associated factors (TRAFs), the activation of transcrip-
tion factors NF-B, c-Fos, and NFATc1. It has been also demon-
strated that the mitogen-activated protein kinase (MAPK) signaling
pathways of ERK, JNK, and p38 as well as the phosphatidylinositol
3-kinase (PI3K)–Akt pathway are involved in RANKL-dependent
OC differentiation and function.5-7
Considering the balance between the activities of osteoblast and
OC for bone homeostasis, it is conceivable that the negative
regulators of osteoclastogenesis might be equally important as
pro-osteoclastogenic factors for maintaining normal bone mass.2 In
this context, type I (IFN-/) and type II (IFN-) IFNs have been
shown to strongly inhibit OC differentiation and function both in
vivo and in vitro. IFN- accelerates proteasomal degradation of
TRAF6, thereby abrogating RANKL-dependent signaling.8 On the
other hand, it has been shown that IFN- inhibits the expression of
c-Fos.9 Recent findings that the members of suppressors of
cytokine signaling (SOCS), which oppose Janus kinase (JAK)/
STAT signaling induced by IFN- and IFN-, reversed the
inhibitory actions of the IFNs on osteoclastogenesis suggest the
involvement of Jak signaling in the IFN-mediated inhibition of
osteoclastogenesis.10-12 However, the role of Jak kinases during
osteoclastogenesis remains to be fully understood.
Many of the skeletal diseases involve unregulated osteoclasto-
genesis leading to excessive bone resorption, which are frequently
observed in osteoporosis, rheumatoid arthritis, periodontal dis-
eases, cancer metastasis, and multiple myeloma.2,5 With increasing
body of evidence that the IFN/Jak/STAT signaling pathway is
involved in osteoclastogenesis, a more detailed understanding of
the role for the components of this pathway during OC differentia-
tion may also provide insights into strategies for the intervention of
bone destructive diseases.
In this study, using a proteomic approach, we discovered that
the expression level of Jak1 is significantly decreased during the
early differentiation of bone marrow macrophages (BMMs) into
pOCs upon RANKL stimulation via a ubiquitin-mediated proteaso-
mal degradation mechanism. Thus, the inhibitory activity of IFN-
on OC differentiation was limited to the early stage of osteoclasto-
genesis due to the lack of Jak1 in the later stages of differentiation.
These results indicate the existence of a mode of regulation in OC
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precursors that negates the negative regulatory effect of IFN on
osteoclastogenesis by reducing Jak1 upon RANKL stimulation,
which may in part explain the excessive osteoclastogenesis in
rheumatoid arthritis despite high levels of IFN- in synovium.
Methods
Animals and reagents
ICR mice at 5 weeks old were obtained from Charles River Laboratories
(Wilmington, MA). Wild-type (WT) and STAT1-deficient mice (129S6/
SvEv background) aged 5 weeks were from Taconic (Aramachi, Japan).
Animal experimental protocols were approved by the committee on the care
and use of animals in research at Seoul National University. Recombinant
human soluble RANKL and human M-CSF were purchased from Pepro-
Tech (Rocky Hill, NJ). Leukocyte acid phosphatase assay kit was from
Sigma (St Louis, MO). Lipofectamine 2000 was from Invitrogen Life
Technologies (Carlsbad, CA). Antibodies (Abs) against ubiquitin (FL-76)
and Jak1 (HR-785) were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). Anti–-actin (AC-74) was from Sigma. Phosphospecific Abs for
STAT1 (Tyr701), STAT3 (Tyr705), STAT3 (Ser727), and STAT5 (Tyr694)
were from Cell Signaling Technology (Beverly, MA). Anti-STAT1, anti-
STAT3, and anti-STAT5 Abs were also purchased from Cell Signaling
Technology. Anti-Jak1(73) and anti–phospho-Jak1 (Tyr1022/Tyr1023) Abs
were from BD Biosciences Pharmingen (San Diego, CA) and Abcam
(Cambridge, United Kingdom), respectively. Proteasome inhibitor MG132
was obtained from Calbiochem (La Jolla, CA). All other chemicals were
purchased from Sigma.
Cell-surface biotinylation and purification of biotinylated
proteins
BMMs (4  105 cells/well in 6-well plates) were cultured with 30 ng/mL
M-CSF alone or M-CSF plus 200 ng/mL RANKL for 36 hours. A total of
2  107 cells were surface biotinylated using the Pinpoint cell-surface
protein isolation kit (Pierce, Rockford, IL) following the manufacturer’s
instructions, lysed, and subjected to an immobilized NeutrAvidin gel
column (Pierce). The biotinylated proteins were eluted with SDS-PAGE
sample buffer.
Gel electrophoresis and protein digestion
Biotinylated proteins were loaded onto a 16  16-cm 8% to 16% gradient
SDS-PAGE gel (Bio-Rad, Hercules, CA). After separation, gel was stained
with SYPRO Ruby dye (Invitrogen) and visualized on a UV illuminator.
After cutting protein bands showing differential expression between
macrophages and pOCs, proteins were in-gel digested and eluted out of the
gel for subsequent liquid chromatography/tandem mass spectrometry
(LC/MS/MS) analyses.
LC/MS/MS experiments and data analyses
Digested protein bands were separately analyzed by nano-LC/MS/MS
equipped with an LTQ-FT mass spectrometer (Thermo Electron, San Jose,
CA) and an Agilent 1100 Series NanoLC pump (Agilent Technologies, Palo
Alto, CA). Data from the mass spectrometer were analyzed by using the
Bioworks 3.2 software (Thermo Electron) using a database constructed by
combining the mouse International Protein Index database (ipi.MOUSE.
v.3.10, ftp://ftp.ebi.ac.uk, downloaded 2005.9.24)13 and common contami-
nant proteins such as trypsin and keratin. The search results were
subsequently evaluated by PeptideProphet14 and a home-built software.15 A
detailed description of LC/MS/MS experiments is included in Document S1
(available on the Blood website; see the Supplemental Materials link at the
top of the online article).
Immunoprecipitation and immunoblotting
Immunoprecipitation and Western blotting were performed as described
previously.16 For experiments requiring multiple Western blots using
several phosphospecific antibodies, lysates were divided into same amounts
and subjected to SDS-PAGE and immunoblotting individually. Each
membrane was stripped no more than 3 times. Although actin blots for
loading control were done for each membrane, only 1 representative blot
was shown. For the quantification of band intensities, developed films were
scanned (PowerLook1100; Umax, Taipei, Taiwan) and analyzed by Total-
Lab gel image analysis software (Nonlinear Dynamics, Newcastle, United
Kingdom). The Jak1 protein expression was normalized using the actin
band density of same lane to compensate for the protein loading.
Quantitative PCR analysis
Total RNAs were isolated using the RNeasy kit (Qiagen, Hilden, Germany),
and 1 g RNA was reverse transcribed with the AccuPower kit (Bioneer,
Daejon, Korea) according to the manufacturer’s instructions. For quantita-
tive real-time polymerase chain reaction (PCR) analyses, 4 g cDNA was
amplified with SYBR green PCR master mix (Applied Biosystems,
Warrington, United Kingdom) in a MicroAmp optical tube using an AB
7500 instrument (Applied Biosystems) for 30 cycles of 15-second denatur-
ation at 95°C and 1-minute amplification at 60°C. The PCR primer
sequences were as follows: Jak1, 5-GTCCCTGAAGCCTGAGAGTG-3
(forward) and 5-CTTGATACCATTGCCTCCGT-3 (reverse); and HPRT,
5-CCTAAGATGAGCGCAAGTTG-3 (forward) and 5-CCACAGGGAC-
TAGAACACCTGCTAA-3 (reverse). Data were analyzed by 7500 system
sequence detection software (version 1.3; Applied Biosystems), and the
mRNA expression level of Jak1 was normalized using the level of HPRT to
be presented as relative expression.
OC differentiation
Mouse bone marrow cells, isolated by flushing the marrow space of femora
and tibiae, were incubated overnight on culture dishes in –modified Eagle
medium (MEM) supplemented with 10% fetal bovine serum (FBS). After
discarding adherent cells, cells were further incubated with 20 ng/mL
M-CSF on Petri dishes. BMMs became adherent after a 3-day culture and
were used as OC precursor cells.17 These cells were differentiated into OCs
by incubating 3  104 cells/well in 48-well plates with 30 ng/mL M-CSF
and 100 ng/mL RANKL. At the end of incubation, cells were stained for
TRAP activity using a leukocyte acid phosphatase assay kit (Sigma). Upon
observation under light microscope (100 magnification with an Olympus
BX51 microscope [Olympus, Center Valley, PA], with 10/0.30 Uplan FL
N objective equipped with a Spot Insight digital camera system [Diagnos-
tics Instruments, Sterling Heights, MI]), cells positive for TRAP activity
with 3 or more nuclei were counted as multinuclear OCs, while TRAP
cells with less than 3 nuclei were regarded as pOCs. Although it usually
took 2 days in our experimental conditions for the cells to differentiate into
pOCs and 3 days to differentiate into OCs, the exact time required for
differentiation slightly varied between experiments (eg, the osteoclastogen-
esis was slower in virus-infected cells).
Plasmids
pMX-IRES-GFP mouse Jak1WT and Jak1V658F18 were previously de-
scribed, and human Tyk2WT was cloned into pREX-IRES-CD4 vector. For
Jak1 knock-down experiments, oligonucleotides for siRNA were generated
by targeting a 21-base sequence starting from the number 701 of mouse
Jak1 (GeneBank accession number NM_146145). The resulting oligonucle-
otide sequences of 5-GATCCCGTTATTCGCATCCTGGTAAGAAT-
TGATATCCGTTCTTACCAGGATGCGAATAATTTTTTCCAAA-3 and
5-AGCTTTTGGAAAAAATTATTCGCATCCTGGTAAGAACGGATA-
TCAATTCTTACCAGGATGCGAATAACGG-3 were annealed and li-
gated into pSuper-retro vector (Oligoengine, Seattle, WA) using BamHI and
HindIII sites. For STAT3 knock-down experiments, oligonucleotides for
siRNA were generated by targeting a 21-base sequence starting from the
number 510 of mouse STAT3 (GeneBank accession number NM_213659).
The resulting oligonucleotide sequences were 5-GATCCCGTTGTAGTT-
GAAATCAAAGTCGTTGATATCCGGGACTTT-3 and 5-AGCTT-
TTGGAAAAAATTGTAGTTGAAATCAAAATCAACGACTTTGATTTC-
AACTACAACGG-3.
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Retroviral gene transfer
Retroviruses were packaged by transfecting pMX-IRES-GFP-Jak1WT,
-Jak1V658F, pSuper-retro-Jak1siRNA, and pSuper-retro-STAT3siRNA
plasmids into Plat-E cells as described previously.16 Retroviral infection
was performed by incubating cells with virus-containing media with the
addition of 10 g/mL polybrene. After overnight incubation, cells were
either induced for OC differentiation or used for signaling experi-
ments.16 For the siRNA experiments, successful down-regulation of
proteins required 24 to 48 hours of incubation after viral infection
depending on the target.
STAT3 DNA binding assay
The DNA binding activity of STAT3 was determined in nuclear extracts
(200 g protein) from IFN-–stimulated cells using the Duoset IC
human/mouse active STAT3 activity assay kit (R&D Systems, Minneapolis,
MN) following the manufacturer’s protocol.
Statistical analysis
The Student t test was used to determine the significance of differences
between results.
Results
Jak1 expression is decreased during BMM differentiation
into pOCs
In an attempt to explore molecular mechanisms underlying macro-
phage differentiation into OCs, we used a proteomic approach to
ascertain differentially expressed proteins during the early stage of
OC differentiation under the assumption that those differentially
regulated proteins may have a role in OC differentiation. After
culturing BMMs in the presence of 30 ng/mL M-CSF alone or in
combination with 200 ng/mL RANKL for 36 hours, surface
proteins were biotinylated, subjected to SDS-PAGE, and visualized
(Figure 1A). There were 4 protein bands of which the intensity was
distinctively increased, and 8 protein bands of which the intensity
was decreased. Those protein bands were cut off of the gel and
were analyzed by LC/MS/MS experiments. Positively identified
proteins from the approximately 130-kDa band showing decreased
expression upon RANKL treatment (Figure 1A arrow) included
mouse Jak1 tyrosine kinase. A total of 3 unique Jak1 peptide
sequences were identified (Table 1). To confirm the decrease of
Jak1 protein by RANKL treatment, total-cell lysates of BMMs
treated with M-CSF alone or M-CSF plus RANKL for 36 hours
were subjected to Western blot analysis. Figure 1B confirms that
the expression of Jak1 is significantly decreased by treatment with
RANKL for 36 hours.
Jak1 protein but not the mRNA expression level is affected by
RANKL treatment
BMMs were treated with M-CSF and 0 to 500 ng/mL RANKL for
24 hours, and cell lysates were analyzed for Jak1 expression by
Western blotting (Figure 2A). Jak1 expression was not altered by
incubation with RANKL up to 10 ng/mL. However, 100 ng/mL or
greater concentrations of RANKL significantly reduced Jak1
expression (Figure 2A left panel). Densitometry results from
3 independent experiments showed that Jak1 expression was
reduced to 72.3% plus or minus 6.1% and 50.7% plus or minus
5.2% of control after 100 and 500 ng/mL RANKL treatment,
respectively (Figure 2A right panel). At 48 hours after stimulation,
more profound reduction of Jak1 expression was observed in cells
treated with 100 or 500 ng/mL RANKL, but not in BMMs treated
with 10 ng/mL or less RANKL (data not shown). We next
investigated the time-course of Jak1 expression levels upon
RANKL stimulation. Results in Figure 2B show that the protein
expression of Jak1 started to significantly decrease at 24 hours after
RANKL stimulation (Figure 2B left panel). When Jak1 band
densities were analyzed by densitometry from 3 independent
experiments (Figure 2B right panel), the mean Jak1 density at
24 hours and 48 hours after RANKL stimulation was 72.6% plus or
minus 6.7% and 45.6% plus or minus 7.4% of control (0 hours),
respectively. A similar pattern of reduction in Jak1 expression level
was also observed during the RANKL-induced osteoclastogenesis
in RAW264.7 cells (Figure S1). However, Jak2 and Jak3 proteins
were not down-regulated by RANKL in BMMs (Figure S2). The
reduced expression of Jak1 and the formation of TRAP
multinuclear OCs seemed to correlate. Figure 2C shows that the
formation of OCs was minimal after the treatment of BMMs with
10 ng/mL RANKL for 72 hours. However, 100 or 500 ng/mL
RANKL, which reduced Jak1 expression significantly, induced
efficient formation of OCs. Similarly, the formation of mono-
nuclear pOCs measured at 48 hours after stimulation also corre-
lated with the RANKL-dependent reduction of Jak1 expression
(data not shown). Next, we tested if Jak1 expression was regulated
at the transcription level. BMMs were treated with 30 ng/mL
M-CSF and 0 to 500 ng/mL RANKL for 48 hours, and total RNAs
were isolated. Quantitative real-time PCR analysis resulted in no
significant difference in Jak1 mRNA levels during a 48-hour
treatment of cells with 0 to 500 ng/mL RANKL (Figure 2D) and
during the course of 48 hours of incubation with 100 ng/mL
Figure 1. Proteomic identification of Jak1 as a protein whose expression was
decreased during early osteoclast differentiation. (A) BMMs were incubated with
30 ng/mL M-CSF in combination with 200 ng/mL RANKL for 36 hours. At the end of
incubation, cell-surface proteins were biotinylated and isolated. The biotinylated
proteins were separated on an 8% to 16% SDS gel and visualized by SYPRO Ruby
staining. Protein bands showing differential expression in RANKL-stimulated cells
were subjected to LC/MS/MS analysis for protein identification. Arrow indicates the
protein band in which Jak1 was included. (B) The decreased expression of Jak1 in
RANKL-stimulated cells was confirmed by Western blotting. BMMs were cultured
with 30 ng/mL M-CSF alone (M) or M-CSF plus 200 ng/mL RANKL (MR) for 36 hours,
and total-cell lysates were subjected to SDS-PAGE followed by immunoblotting using
anti-Jak1 antibody. Antiactin blot was shown to ensure same loading between the
2 lanes.
Table 1. Peptide sequences identified as Jak1 in the protein band in
Figure 1A after tryptic digestion followed by LC/MS/MS analysis
Peptide sequence Amino acid no.
VPEATPLLDASSLEYLFAQGQYDLIK 143-168
DVENIMVEEFVEGGPLDLFMHR 659-680
TTFQNLIEGFEALLK 1139-1153
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RANKL (Figure 2E). Similarly, reverse transcription (RT)–PCR
analysis showed no significant change in the Jak1 mRNA level
(Figure S3).
RANKL induces ubiquitination of Jak1
Since Jak1 protein expression level was substantially reduced
after RANKL stimulation without any significant change in the
mRNA level, we hypothesized that Jak1 protein expression
might be regulated by ubiquitin-mediated proteasomal degrada-
tion. To test this possibility, BMMs were grown in the presence
of 30 ng/mL M-CSF plus 100 ng/mL RANKL, and cell lysates
were subjected to immunoprecipitation using Jak1-specific Ab
followed by Western blotting with antiubiquitin Ab (Figure 3A).
Upon stimulation with RANKL for 24 hours and 48 hours,
extensively ubiquitinated protein bands having 130 kDa or
higher molecular weights were immunoprecipitated with anti-
Jak1 Ab, whereas Jak1 immunoprecipitates from control lysates
(0 hours) showed only slight levels of basal ubiquitination.
When the same membrane was stripped and reprobed with
anti-Jak1 Ab, protein bands having higher molecular weight
than that of the unmodified Jak1 (approximately 130 kDa),
corresponding to the ubiquitinated Jak1, appeared in 24- and
48-hour stimulation samples, which were absent in control. To
further confirm the Jak1 degradation via a ubiquitin-mediated
proteasome pathway, BMMs were stimulated with RANKL for
48 hours, and a proteasome inhibitor MG132 was added during
the final 4 hours of incubation (Figure 3B). Western blotting
revealed that the incubation of BMMs with the increasing
concentrations of MG132 resulted in the increased level of Jak1
Figure 2. Jak1 protein but not mRNA expression level was decreased during RANKL-induced osteoclast differentiation. (A) BMMs were cultured with 30 ng/mL M-CSF
in the presence of indicated concentrations of RANKL for 24 hours. Lysates were subjected to Western blotting, and Jak1 expression was determined by enhanced
chemiluminescence. Jak1 band densities were quantified as described in “Immunoprecipitation and immunoblotting” (right panel). (B) BMMs were cultured with 30 ng/mL
M-CSF in the presence of 100 ng/mL RANKL for indicated times, and total-cell lysates were subjected to Western blotting using anti-Jak1 antibody (left panel). Jak1 expression
was quantified as in panel A (right). (C) BMMs were cultured in the presence of 30 ng/mL M-CSF and 1 to 500 ng/mL RANKL for 3 days, and the formation of TRAP
multinuclear OCs was observed. Cells were counted in 3 random fields under the microscope and the average number plus or minus SD was shown. Similar results were
obtained from 2 independent experiments. (D) BMMs were cultured for 48 hours in the presence of 30 ng/mL M-CSF and 0 to 500 ng/mL RANKL, and total RNAs were isolated,
reverse-transcribed, and subjected to quantitative real-time PCR analysis for Jak1. Jak1 expression levels were normalized by the levels of HPRT in each sample. (E) RNA
samples from the cells cultured as in panel B were subjected to quantitative real-time PCR analysis. Western blot images are representative of at least 3 experiments with
similar results. Values in graphs are expressed as means (	 SD) from 3 (A,D) or 4 (B,E) experiments. *P 
 .05; **P 
 .01 versus control values.
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in cell lysates, suggesting that the proteasome-mediated degra-
dation of Jak1 was blocked by MG132. Taken together, these
results suggested that the decreased level of Jak1 following
RANKL stimulation resulted from the RANKL-induced ubiquiti-
nation of Jak1 and subsequent proteasome-mediated degradation.
Jak1 expression on OC precursors correlates with the IFN-
susceptibility during OC differentiation
We next examined the physiologic significance of decreased
Jak1 expression in OC precursor cells during RANKL-induced
osteoclastogenesis. Recently, it has been demonstrated that
IFN- exerts negative effects on RANKL-induced OC forma-
tion,9 which was confirmed in our study by culturing BMMs
with RANKL in the presence of IFN- (Figure 4A). The
presence of IFN- significantly reduced the formation of OCs as
determined by the dramatically reduced formation of TRAP
large multinuclear cells after 3-day culture with RANKL (Figure
4B). When an increasing concentration of IFN- was used to
inhibit OC formation, as little as 2 U/mL IFN- was sufficient to
significantly inhibit osteoclastogenesis induced by 100 ng/mL
RANKL (Figure 4C). The number of OCs formed under the
presence of 10 U/mL IFN- for 3 days was less than 10% of
those in the absence of IFN-. Since the lack of Jak1 was known
to be responsible for the unresponsiveness of cells to IFNs,19 we
postulated that pOCs, in which Jak1 expression is significantly
reduced (Figure 2), might be resistant to the inhibition of
osteoclastogenesis by IFN-. To test this, BMMs were first
cultured with RANKL for 2 days, treated with 10 U/mL IFN-,
and stained for TRAP activity at day 3 (Figure 4D). As
predicted, IFN- had no negative effect on OC differentiation
when added at 48 hours after RANKL stimulation (Figure 4E).
There was no significant difference in the OC numbers with the
tested concentrations of IFN- (1-10 U/mL; Figure 4F). The
expression of type I IFN receptor was not affected by RANKL
up to 500 ng/mL at 48 hours after stimulation (data not shown).
To further dissect the time point when BMMs cultured with
RANKL become resistant to the negative effect of IFN-,
10 U/mL IFN- was added at different times after the addition
of RANKL (Figure S4). When IFN- was added at the start of
Figure 3. Jak1 was ubiquitinated upon RANKL stimulation. (A) BMMs were
incubated with 30 ng/mL M-CSF and 100 ng/mL RANKL for the indicated times, and
total-cell lysates were subjected to immunoprecipitation using anti-Jak1 antibody.
Immunoprecipitates were separated by SDS-PAGE and immunoblotted using antiu-
biquitin antibody. The blot was stripped and reprobed for Jak1. Jak1 and actin
expression was also examined from a small portion of input lysates. (B) BMMs were
cultured with M-CSF (30 ng/mL) and RANKL (100 ng/mL) for 48 hours. MG132 was
added for the final 4 hours of incubation. Total-cell lysates were subjected to Western
blotting for the examination of Jak1 expression. (A,B) Blots are representative of at
least 3 experiments with similar results.
Figure 4. pOCs were not susceptible to the IFN-–mediated inhibition
of osteoclastogenesis. (A) BMMs were cultured with M-CSF (30 ng/mL)
and RANKL (100 ng/mL) for 3 days. IFN- was added at the start of culture
for experiments described in panels B and C. (B) At the end of culture, cells
were fixed and stained for TRAP activity. Osteoclasts were identified as
TRAP (purple) multinuclear cells. MR represents M-CSF plus RANKL.
Results are representative of at least 3 experiments using 10 U/mL IFN-.
(C) OC numbers were counted after a 3-day culture of BMMs with M-CSF
and RANKL in combination with IFN-. Cells were counted in 3 random
fields. Results are presented as means plus or minus SD and are
representative of at least 3 experiments with similar results. Asterisks
represent statistical difference between the values obtained from cells
cultured with or without IFN- in the presence of M-CSF and RANKL
(*P 
 .05; **P 
 .01). (D) BMMs were first differentiated into pOCs by
incubating cells with M-CSF and RANKL for 2 days, and IFN- was added
at the end of day 2 for experiments in panels E and F. (E) After a 3-day
culture, cells were stained for TRAP activity. (F) OC numbers were counted
after a 3-day culture of BMMs with M-CSF and RANKL. Varying concentra-
tions of IFN- were added for the final 24 hours. Data are presented as in
panel C.
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culture, there was significant reduction in the formation of OCs.
However, when IFN- was added at 24 hours or 48 hours after
RANKL addition, no significant decrease in the OC number was
observed. Furthermore, presence of IFN- only for the first
24 hours after RANKL stimulation was enough to inhibit
osteoclastogenesis. Thus, it seemed that the inhibitory action of
IFN- on osteoclastogenesis was limited to the early stage of
OC differentiation, when Jak1 expression is still intact.
Jak1 overexpression in pOCs elicits IFN-–mediated inhibition
of osteoclastogenesis
Next, we hypothesized that the forced expression of Jak1 into
pOCs would induce these cells to be sensitive to the inhibitory
effect of IFN-. To test this, BMMs were first cultured in the
presence of RANKL for 2 days, and cells were infected with
retroviruses harboring WT Jak1 or constitutively active Jak1
(Figure 5A). Figure 5B shows that the infection of cells with
viruses harboring WT Jak1 (pMX-Jak1WT) or constitutively active
Jak1 (pMX-Jak1CA; Jak1V658F)18 successfully increased Jak1
protein expression. After viral infection, pOCs were further differ-
entiated into OCs using RANKL in the presence of IFN-.
Uninfected and control virus–infected pOCs showed no difference
in the numbers of differentiated OCs in the presence or absence of
IFN- (Figure 5C). However, the overexpression of WT Jak1 in
pOCs sensitized pOCs to the antiosteoclastogenic effect of IFN-,
leading to the significantly reduced formation of OCs in the
presence of IFN-. An approximately 60% reduction in the
numbers of TRAP OCs was observed (Figure 5D). Finally,
overexpression of constitutively active Jak1 inhibited OC differen-
tiation from pOCs independent of IFN treatment.
Since the addition of the proteasome inhibitor MG132 signifi-
cantly increased Jak1 expression (Figure 3B), the effect of IFN-
on osteoclastogenesis in the presence of MG132 was tested. BMMs
were first cultured for 2 days with 100 ng/mL RANKL, and 1 M
MG132 was added during the final 4 hours of incubation (Figure
5A). Although the addition of MG132 alone slightly decreased the
OC numbers, treatment of pOCs with MG132 resensitized cells to
the inhibitory effect of IFN- (Figure S5B). While IFN- at a
10 U/mL concentration was ineffective to inhibit OC formation
when added at 48 hours after RANKL stimulation, as little as
1 U/mL IFN- significantly reduced the numbers of OCs formed
from the precursors pretreated with MG132. Treatment of cells
with MG132 in our experimental scheme showed no cytotoxicity
as tested by a tetrazolium-based assay (data not shown).
Jak1 knock-down protects BMMs from the IFN-–mediated
inhibition of osteoclastogenesis
Since the overexpression of Jak1 in pOCs conferred IFN-
sensitivity during RANKL-induced osteoclastogenesis, it was
conversely expected that the knock-down of Jak1 in BMMs
would protect these OC precursors from the IFN-–mediated
inhibition of OC differentiation. To test this, the expression of
Jak1 in BMMs were down-regulated by introducing Jak1-
specific siRNA (Jak1siRNA) via retroviral infection (Figure
6A). Compared with the cells infected with control viruses, cells
cultured with viruses harboring Jak1siRNA showed significantly
reduced Jak1 expression (Figure 6B). These BMMs were then
differentiated into OCs using RANKL, and the inhibitory effect
of IFN- on the osteoclastogenesis was examined. As shown in
Figure 6C, introduction of siRNA specific for Jak1 protected
BMMs from the inhibitory effect of IFN- on the RANKL-
induced OC differentiation, while cells infected with control
viruses failed to differentiate into OCs in the presence of IFN-.
When the increasing concentrations of IFN- were used,
2 U/mL IFN- was sufficient to significantly inhibit osteoclasto-
genesis in BMMs infected with control virus (Figure 6D).
Similarly, IFN- at 2 U/mL or greater concentrations signifi-
cantly reduced the formation of TRAP OCs upon RANKL
stimulation in Jak1siRNA virus–infected BMMs. However,
consistently higher number of OCs was observed in Jak1
knocked-down cells after IFN- addition when compared with
control virus-infected cells. Specifically, 1.4-fold and 2.8-fold
more OCs were observed in Jak1 knocked-down cells than in
control virus-infected cells in the presence of 5 U/mL and
10 U/mL IFN-, respectively.
The Jak1-dependent negative regulation of osteoclastogenesis
by IFN- is mediated through STAT3
We next examined the signaling pathways affected upon IFN-
stimulation when Jak1 expression is decreased. BMMs were
infected with control viruses or viruses harboring Jak1siRNA
plasmid and stimulated with RANKL, IFN-, or RANKL plus
IFN- for 5 minutes or 30 minutes; cell lysates were subjected
to Western blotting using phosphospecific antibodies (Figure
7A). Treatment of cells with IFN- or RANKL in combination
with IFN- significantly induced STAT1 and STAT3 tyrosine
phosphorylation at 30 minutes after stimulation while inducing
slight phosphorylation in STAT5. However, in Jak1 knocked-
down cells, IFN-–induced STAT3 tyrosine phosphorylation
Figure 5. Jak1 overexpression sensitized pOCs to the IFN--mediated inhibi-
tion of osteoclastogenesis. (A) BMMs were first differentiated into pOCs by
culturing with M-CSF (30 ng/mL) and RANKL (100 ng/mL). After the infection with
viruses harboring empty vector (pMX), WT Jak1 (pMX-Jak1WT), or constitutively
active Jak1 (pMX-Jak1CA), cells were further differentiated into OCs with RANKL in
the presence or absence of IFN- (10 U/mL). (B) At 1 day after Jak1 viral infection,
total-cell lysates were investigated for Jak1 expression by Western blotting. (C) At the
end of culture, cells were stained for TRAP activity. MR represents M-CSF plus
RANKL. Results are representative of at least 3 experiments with similar results.
(D) OC numbers in panel C were counted. Data are means (	 SD) from 3 random
fields in representative experiment.
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was clearly reduced, although STAT1 phosphorylation was
nearly unaffected. STAT5 tyrosine phosphorylation was only
slightly reduced at 30 minutes after IFN- stimulation in Jak1
knocked-down cells compared with control BMMs. There was
similar reduction of STAT3 serine phosphorylation after IFN-
stimulation in Jak1 knocked-down cells. Similar selective
reduction in the IFN-–induced phosphorylation of STAT3 was
also observed in pOCs (Figure S6A). To confirm the reduced
STAT3 activity in Jak1 knocked-down cells, STAT3 binding to
the STAT3 consensus binding site was examined in nuclear
extracts from control and Jak1siRNA virus–infected BMMs
(Figure 7B). In control virus-infected BMMs, stimulation with
100 U/mL IFN- for 30 minutes significantly induced STAT3
DNA binding activity. However, in Jak1 knocked-down cells,
STAT3 DNA binding upon IFN- stimulation was greatly
reduced. Since Jak1 knock-down seemed to prominently hamper
IFN-–dependent STAT3 activation, the role of STAT3 during
IFN-–mediated inhibition of osteoclastogenesis was investi-
gated. BMMs were infected with STAT3 siRNA viruses (Figure
7C), and the reduction of STAT3 expression was confirmed by
Western blotting in control and STAT3 knocked-down BMMs
(Figure 7D). When these BMMs were cultured with RANKL in
the presence of IFN-, STAT3 knocked-down BMMs were
clearly protected from the inhibition of osteoclastogenesis by
IFN- (Figures 7E, S6B). While incubating cells with IFN- for
the first 24 hours following RANKL stimulation was enough to
significantly inhibit osteoclastogenesis, more than 3 times the
number of OCs were observed in STAT3 knocked-down cells
compared with control in the presence of 10 U/mL IFN-. The
STAT3 activity in BMMs appeared to be independent on STAT1
expression, as we observed similar STAT3 DNA binding activity
upon IFN- stimulation in STAT1 knock-out cells (Figure 7F)
and STAT1 siRNA–infected cells (Figure S7) compared with the
respective control cells. These results suggested that the de-
creased expression of Jak1 and subsequently impeded STAT3
signaling correlates with the lack of IFN-mediated inhibition of
osteoclastogenesis of already committed pOCs.
Discussion
In the present study, we discovered that the expression of Jak1 is
significantly reduced during the early stage of OC differentiation
by using unbiased proteomic approach. Our results suggested that
Jak1 expression is regulated via ubiquitin-mediated proteasomal
degradation upon RANKL stimulation. To our knowledge, this is
the first evidence that directly shows the ubiquitination of Jak1
during any physiologic process. Recently, it was shown that the
ubiquitin-mediated proteasomal degradation regulates the mem-
bers of the Jak/STAT pathway. Jak2 was reported to be down-
regulated via the ubiquitin-proteasome pathway upon stimulation
of cells by hormones and cytokines such as prolactin, IL-3, and
IFN-.20,21 It was also demonstrated that STAT1 and STAT4 were
ubiquitinated by the ubiquitin E3 ligase SLIM.22 Thus, our results
add to a growing body of evidence that the ubiquitin-mediated
degradation of the Jak/STAT pathway proteins constitutes a novel
mechanism regulating cellular events. At present, several questions
remain to be answered regarding the RANKL-induced ubiquitina-
tion of Jak1, such as signaling pathways resulting in the Jak1
ubiquitination and the identity of ubiquitin E3 ligase.
The role of Jak1 is crucial in signaling events initiated by
cytokines, including IFNs.19,23 However, in spite of increasing
evidence that IFN-mediated signaling is one of the major
mechanisms involved in the inhibition of osteoclastogenesis, the
role of Jak1 during RANKL-induced OC differentiation has
never been investigated. In this study, we showed that the
decreased expression of Jak1 during early OC differentiation
correlated with the IFN-responsiveness of OC precursors. The
“commitment” of OC precursors (ie, resistance to the IFN-
mediated inhibition of osteoclastogenesis) seemed to occur
within first 24 hours following RANKL stimulation, since the
existence of IFN- in the culture media during this 24-hour
period significantly inhibited osteoclastogenesis, while OC
differentiation occurred independent of IFN- thereafter. Further-
more, once BMMs were cultured with IFN- for the first
24 hours and washed out, BMMs could not differentiate into
mature OCs up to 1 week (data not shown), while it usually took
3 days in our culture system for BMMs to differentiate into OCs.
The importance of the Jak1 in this commitment step was
confirmed by showing that IFN- could inhibit osteoclastogen-
esis at 48 hours after RANKL stimulation, far beyond the
normal commitment stage, when Jak1 was overexpressed.
Forced expression of constitutive active Jak1 resulted in the
IFN-independent suppression of osteoclastogenesis. Further-
more, inhibition of the ubiquitin-mediated degradation of Jak1
by proteasome inhibitor also rendered IFN responsiveness
beyond this commitment stage (48 hours after RANKL stimula-
tion). On the other hand, down-regulation of Jak1 by siRNA
protected OC precursors from the negative regulation by IFN-,
confirming the crucial role of Jak1 during OC differentiation.
Our results are in accordance with those reported by Mochizuki
et al, which showed that the OC lineage commitment occurred
within the first 24 hours after RANKL stimulation.24 In their
report, those committed (treated with RANKL for 24 hours)
cells became resistant to the inhibition of osteoclastogenesis by
GM-CSF, IFN-, and IL-4. From our perspective, it is likely that
the regulation of Jak1 expression demonstrated in this study is
Figure 6. Jak1 knock-down protected BMMs from the IFN--mediated inhibition
of osteoclastogenesis. (A) BMMs were first infected with viruses harboring empty
vector (pSuper) or Jak1 siRNA construct (pSuper-Jak1siRNA). After 24 hours, cells
were stimulated with RANKL (100 ng/mL) to induce OC differentiation in the presence
or absence of IFN-. (B) At 1 day after Jak1 siRNA viral infection, total-cell lysates
were examined for Jak1 expression by Western blotting. (C) At the end of culture,
cells were stained for TRAP activity. MR represents M-CSF plus RANKL. IFN- was
used at 10 U/mL. Results are representative of at least 3 experiments with similar
results. (D) OC numbers in experiments using varying concentrations of IFN- were
counted. Data are means (	 SD) from 3 random fields in representative experiment.
Asterisks represent statistical difference between the values obtained from cells
cultured in the presence or absence of IFN- with M-CSF and RANKL (*P 
 .05;
**P 
 .01). Daggers represent significant difference between pSuper- and pSuper-
Jak1siRNA–infected cells at the same IFN- concentration (†P 
 .05; ‡P 
 .01).
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involved in the OC lineage commitment at least in the protection
from the inhibitory action of IFN-.
Takayanagi et al suggested that IFN- might inhibit RANKL-
induced osteoclastogenesis via a negative feedback mechanism, since
RANKL stimulated generation of endogenous IFN-.9 We could
observe no significant increase in the RANKL-induced osteoclastogen-
esis in Jak1 knocked-down BMMs compared with control cells (Figure
6). Theses results can be at least partially explained by the fact that
RANKL-induced expression of SOCS1 and SOCS3 were reduced in
Jak1 knocked-down BMMs (Figure S8). Since SOCS proteins were
reported to protect osteoclastogenesis from the inhibition by RANKL-
induced endogenous IFN-,11,12 it is possible that the effects of
decreased Jak1 expression and decrease in the RANKL-induced SOCS
proteins were balanced out.
STAT proteins have been suggested as mediators of negative
signaling by IFNs during osteoclastogenesis. STAT1 played a crucial
role in IFN-mediated inhibition of osteoclastogenesis since STAT1-
deficient precursor cells were resistant to the suppression of OC
differentiation by IFN- and IFN-.8,9 Hematopoietic cell–specific
STAT3-deficient mice were described to show osteoporotic phenotype
with increased number of OCs, suggesting an involvement of this
member of STAT family proteins in the negative regulation of osteoclas-
togenesis.25 We observed significantly impaired STAT3 phosphoryla-
tion, and to a lesser extent, reduced STAT5 phosphorylation upon
stimulation with IFN- in Jak1 knocked-down BMMs as well as in
pOCs compared with control BMMs (Figure 7). Furthermore, STAT3
knocked-down BMMs could differentiate into OCs in the presence of
IFN-. On the other hand, there was no significant difference in the
IFN-–induced tyrosine phosphorylation of STAT1 in Jak1 knocked-
down BMMs and in pOCs compared with control BMMs (Figures 7A,
S6A). The overexpression of Tyk2 in BMMs resulted in more potent
phosphorylation of STAT1 upon IFN- stimulation (Figure S9), suggest-
ing that Tyk2 might be playing a compensatory role to activate STAT1
when Jak1 is down-regulated. Thus, it is likely that STAT3 is playing
important role downstream of Jak1 during IFN-–mediated inhibition
of osteoclastogenesis described in the present study. Although the exact
mechanism by which STAT3 modulates osteoclastogenesis still needs to
be unveiled, it was demonstrated that the expression of c-Fos was
Figure 7. STAT3 signaling pathway was involved in the IFN-–mediated inhibition of osteoclastogenesis. (A) BMMs were infected with viruses harboring empty vector
(pSuper) or Jak1 siRNA construct (Jak1siRNA). At 1 day after viral infection, cells were stimulated with IFN- (100 U/mL) in combination with RANKL (500 ng/mL) for the
indicated times. Total-cell lysates were subjected to Western blotting using phosphospecific antibodies. The expression of each protein was examined by directly stripping and
reprobing the same membrane used to detect the phosphoform of the protein with respective antibody. (B) Vector or Jak1siRNA-infected BMMs were stimulated with 100 U/mL
IFN- for 30 minutes. Nuclear extracts were prepared and assayed for the DNA binding activities of STAT3 as described in “Methods.” Excess unlabeled oligo DNA was added
to confirm the specificity of assay. (C) BMMs were first infected with viruses harboring empty vector (pSuper) or STAT3 siRNA construct (pSuper-STAT3siRNA). (D) After
48 hours, total-cell lysates were examined for STAT3 expression by Western blotting. Antiactin blot was shown to ensure same loading between 2 lanes. (E) Cells in panel D
were incubated with 10 U/mL IFN- for 24 hours and further incubated with 100 ng/mL RANKL for 3 days in the presence of 30 ng/mL M-CSF. At the end of culture, cells were
stained for TRAP activity. The number of TRAP multinuclear OCs was counted from 3 random fields under microscope. Data are means plus or minus SD and are
representative of 3 independent experiments. Asterisks represent statistical difference (**P 
 .01). MR represents M-CSF plus RANKL. (F) WT or STAT1-deficient BMMs were
stimulated with 100 U/mL IFN- for 30 minutes. Nuclear extracts were prepared and assayed for the DNA binding activities of STAT3 as described in “STAT3 DNA binding
assay.” Excess unlabeled oligo DNA was added to confirm the specificity of assay. Data are means (	 SEM) of 5 independent experiments. Asterisks represent statistical
difference (*P 
 .05; **P 
 .01).
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significantly increased in STAT3-deficient BMMs.25 Since IFN- is
known to inhibit osteoclastogenesis by down-regulating c-Fos,9 one
possibility is that the reduced Jak1 expression and concomitant reduc-
tion in the STAT3 activity shown in the current study facilitates
osteoclastogenesis by impeding the IFN-–mediated decrease in
c-Fos expression.
Our results may also have implications for skeletal diseases
involving uncontrolled osteoclastogenesis even in the presence
of negative regulators. For example, rheumatoid arthritis (RA)
is characterized by the destruction of cartilage and bone in joints
with greatly increased OC number and activity.26-28 Surprisingly,
markedly increased expression of IFN- was reported in
synovial tissue from patients with RA,29 in spite of the current
understanding that IFN- suppresses osteoclastogenesis. Further-
more, controlled clinical studies found no significant beneficial
effect of IFN- for the treatment of patients with RA,30 despite
some promising results with animal models.31 Taken together, it
is possible that the reduction of Jak1 expression in RANKL-
primed OC precursors shown in the present study might be
playing a role in protection from the negative effect of high
levels of IFN- in RA joints.
To summarize, we observed the down-regulation of Jak1
resulted from the ubiquitin-mediated degradation during early OC
differentiation of BMMs induced by RANKL. The reduction in the
Jak1 expression level correlated with the resistance to the antioste-
oclastogenic effect of IFN-. The mechanism described in this
study may be a part of the differentiation program that determines
OC lineage commitment.
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